[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-567374-105":53,"doc-detail-567374-en":120},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":113,"head_meta":115,"extra_data":117,"updated_unix":119},105,"en","antiantibiotic-chart-gram-positive-cocci-and-gram-negative-activity-guide","Antiantibiotic Chart - Gram-Positive Cocci and Gram-Negative Activity Guide","","Antiantibiotic Chart is a quick teaching reference organizing antibacterial activity by pathogen groups and drug classes. It compares Gram-positive cocci clusters (including staphylococci and streptococci) versus Gram-negative rods and enteric flora, anaerobes, and atypicals, using symbols for activity levels and resistance development. The guide highlights spectrum patterns across beta-lactams (penicillins, cephalosporins, carbapenems), beta-lactamase inhibitors, and non–beta-lactams (aminoglycosides, fluoroquinolones, macrolides, etc.). It includes a focused section on IV/PO MRSA-related agents and notes key precautions for clinical use.",{"@graph":63,"@context":112},[64,80,95],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":11,"@type":70,"position":76},"https://docshare.wps.com/template/presentations/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/antiantibiotic-chart-gram-positive-cocci-and-gram-negative-activity-guide/567374/",4,{"url":78,"name":59,"@type":81,"author":82,"headline":59,"publisher":85,"fileFormat":88,"inLanguage":57,"description":61,"dateModified":89,"datePublished":89,"encodingFormat":88,"isAccessibleForFree":90,"interactionStatistic":91},"DigitalDocument",{"name":83,"@type":84},"Cipher","Person",{"url":68,"name":86,"@type":87},"DocShare","Organization","application/pdf","2026-10-13",true,{"@type":92,"interactionType":93,"userInteractionCount":4},"InteractionCounter",{"@type":94},"ViewAction",{"@type":96,"mainEntity":97},"FAQPage",[98,104,108],{"name":99,"@type":100,"acceptedAnswer":101},"How should the chart’s activity symbols be interpreted?","Question",{"text":102,"@type":103},"The chart uses symbols where “++” indicates very good activity, “+” OK activity, “+/-” variable or poor, and “0” no activity. “R” denotes resistance developing, with a note to check locally for resistance patterns.","Answer",{"name":105,"@type":100,"acceptedAnswer":106},"What does the chart emphasize about antibiotic activity across Gram-negative pathogens?",{"text":107,"@type":103},"It states that if an antibiotic works on Pseudomonas it has good activity against enteric GNRs, and if it works against enterics it often has activity against respiratory Gram negatives. It also notes relationships for alpha-hemolytic versus beta-hemolytic streptococci for similar reasons.",{"name":109,"@type":100,"acceptedAnswer":110},"Which IV/PO agents are listed for serious MRSA and resistant Gram-positive cocci?",{"text":111,"@type":103},"The MRSA section lists vancomycin, linezolid, daptomycin, telavancin, ceftaroline, tige/erava IV and omadacycline PO, and lefamulin IV/PO. It also provides brief notes on typical strengths, sites of infection, and important cautions (e.g., long-term linezolid concerns with SSRIs, daptomycin inactivation by lung surfactant).","https://schema.org",{"og:url":78,"og:type":114,"og:title":59,"og:site_name":86,"og:description":61},"article",{"robots":116,"canonical":78},"index,follow",{"doc_id":118,"site_id":56},567374,1791866147,{"code":4,"msg":5,"data":121},{"doc_id":118,"user_id":122,"nickname":83,"user_avatar":123,"doc_module":9,"category_id":8,"category_name":11,"doc_title":59,"doc_description":61,"doc_content":124,"file_id":125,"file_url":126,"file_type":127,"file_size":128,"view_count":4,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":73,"language":129,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":130,"faqs":131,"seo_title":132,"seo_description":61,"update_tm":119,"read_time":9},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","|  |  | Gram Positive Cocci (GPC) |  |  |  | Gram Neg (rods = GNR) |  |  | Anaerobes | Atypicals |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| Classification | Antibiotic | Cluster\u003Cbr>= Staph | Streptococcus β↓ & α-hemolytic↓ |  | Entero\u003Cbr>coccus | Resp\u003Cbr>(cocci) | Enteric\u003Cbr>GI flora | Non\u003Cbr>enteric | Bacteroides,\u003Cbr>Clostridium\u003Cbr>(non-dfficile)\u003Cbr>Peptostrep. | Mycoplasma\u003Cbr>Legionella\u003Cbr>Chlamydia\u003Cbr>(pneumonia) |\n| Beta-Lactams\u003Cbr>Penicillins | General Spectrum of Activity → | \u003Cbr>MSSA\u003Cbr>only | Group\u003Cbr>A / B | pneumo,\u003Cbr>Viridans | faecalis\u003Cbr>only | H. flu,\u003Cbr>[M. cat](M. cat) | E. coli,\u003Cbr>Klebsiella | Pseud\u003Cbr>omonas |  |  |\n| Natural | Penicillin G IV/ PenVK PO | +/ - | \u003Cbr>++ | + | + | 0 | 0 | 0 | + | 0 |\n| AntiStaphylococcal | Oxacillin/Nafcillin IV, Dicloxacillin PO | ++ | ++ | + | 0 | 0 | 0 | 0 | 0 | 0 |\n| Aminopenicillins | Amp/Amoxicillin IV/PO | 0 | ++ | \u003Cbr>+ | \u003Cbr>++ | \u003Cbr>+R | +/ - | 0 | + | 0 |\n| Anti-Pseudomonal | Piperacillin/Ticarcillin IV | 0 | + | + | + | + | \u003Cbr>+ | \u003Cbr>++R | + | 0 |\n| Beta-Lactamase Inhibitor added | Clavulanate IV/PO, sulbactam tazobactam, vaborbactam IV | Increase\u003Cbr>by + |  |  |  | Inc by\u003Cbr>+ | Increase\u003Cbr>by + |  | Increase\u003Cbr>by + |  |\n| Cephalosporins 1st Generation | Cefazolin IV/\u003Cbr>Cephalexin PO | \u003Cbr>++ | ++ | +/ - | 0 | +/ - | + | 0 | 0 | 0 |\n| 2nd Generation | Cefuroxime IV/PO | + | ++ | \u003Cbr>+ | 0 | \u003Cbr>+ | + | 0 | +/ - | 0 |\n| Cephamycins | Cefoxitin/Cefotetan IV | 0 | + | 0 | 0 | + | \u003Cbr>+ | 0 | \u003Cbr>+ | 0 |\n| 3rd Generation (PO in between 2nd and 3rd gen) | Ceftriaxone/Cefotaxime IV | + | ++ | \u003Cbr>++ | 0 | \u003Cbr>++ | \u003Cbr>++R | 0 | +/ - | 0 |\n|  | Ceftazidime IV (+ Avibactam for Carb-Resistant Enterics) | 0 | + | 0 | 0 | ++ | ++R | ++R | 0 | 0 |\n| 4th Generation | Cefepime IV | + | ++ | ++ | 0 | ++ | \u003Cbr>++ | \u003Cbr>++R | 0 | 0 |\n| Novel | Ceftolozane-tazo/Cefiderocol | 0 | + | + | 0 | ++ | \u003Cbr>++ | \u003Cbr>++ | +/ - | 0 |\n| Carbapenems | Imipenem, Meropenem IV (+rele/vaborbactam for CRE) | + | + | + | +/ - | ++ | ++ | ++R | ++ | 0 |\n|  | Ertapenem IV | + | ++ | \u003Cbr>++ | 0 | ++ | \u003Cbr>++ | 0 | \u003Cbr>++ | 0 |\n| Monobactam | Aztreonam IV | 0 | 0 | 0 | 0 | ++ | \u003Cbr>++R | \u003Cbr>+ | 0 | 0 |\n| Non β-Lactams | Includes | \u003Cbr>MRSA |  |  | Both sp. |  |  |  |  |  |\n| Aminoglycosides (Use in combo) | Gentamicin, tobramycin, amikacin, plazomicin IV | Synergy\u003Cbr>Only | 0 | 0 |  Synergy\u003Cbr>Only (gent) | + | ++ | ++ | 0 | 0 |\n| Polymyxins | Polymyxin B/Colistin IV | 0 | 0 | 0 | 0 | ++ | ++ | \u003Cbr>++ | 0 | 0 |\n| Sulfonamides | TMP-SMX IV/PO | \u003Cbr>+ | +/ - | +/ - | 0 | + | \u003Cbr>+ | 0 | 0 | 0 |\n| Tetracyclines | Doxycycline IV/PO | \u003Cbr>+ | +/ - | \u003Cbr>+ | + | ++ | +/ - | 0 | +/ - | \u003Cbr>++ |\n| Macrolides | Azithromycin IV/PO | +/ - | + | \u003Cbr>+ | 0 | \u003Cbr>+ | +/ - | 0 | 0 | \u003Cbr>++ |\n| Fluoroquinolones | Ciprofloxacin IV/PO | +/ - | + | +/ - | +/ - | ++ | \u003Cbr>+ | \u003Cbr>+ | 0 | \u003Cbr>++ |\n|  | Levofloxacin IV/PO | +/ - | ++ | \u003Cbr>++ | +/ - | ++ | \u003Cbr>+ | + 750mg | 0 | \u003Cbr>++ |\n|  | Moxifloxacin IV/PO | +/ - | ++ | \u003Cbr>++ | +/ - | ++ | \u003Cbr>+ | 0 | \u003Cbr>+ | \u003Cbr>++ |\n|  | Delafloxacin IV/PO | \u003Cbr>++ | ++ | \u003Cbr>++ | + | ++ | ++ | \u003Cbr>+/++ | ? | ++ |\n| Lincosamide | Clindamycin IV/PO | \u003Cbr>+ | \u003Cbr>+ | \u003Cbr>+ | 0 | 0 | 0 | 0 | \u003Cbr>+ | 0 |\n| Miscellaneous | Metronidazole IV/PO | 0 | 0 | 0 | 0 | 0 | 0 | 0 | \u003Cbr>++ | 0 |\n| ++ Very Good, + OK, +/-Poor or variable, 0 = No activity, R = resistance developing, check locally – Scott Bergman, PharmD, BCIDP: Nebraska Medicine,12-19 |  |  |  |  |  |  |  |  |  |  |\n\nAlthough you will find exceptions, if an antibiotic works on Pseudomonas then it has good activity against enteric GNRs. If it works against enterics, then it will also have activity against the respiratory Gram negatives because they are easiest to kill. If it works on alpha-hemolytic Strep, it usually has activity against beta-hemolytic Strep for the same reason (but not always) . The agents below all treat GPC (Staph and Strep) in skin infections  \n\n| \u003Cbr>++ MRSA IV Agents | VRE\u003Cbr>=fae","cbCaio6Mg13bAWa9","https://ap.wps.com/l/cbCaio6Mg13bAWa9","pdf",122515,"English","# Antibiotic spectrum by organism group\n## Activity levels and resistance notation\n## Beta-lactams and cephalosporin generations\n## Carbapenems, monobactam, and non–beta-lactams\n# MRSA-focused agents and clinical cautions","[{\"question\":\"How should the chart’s activity symbols be interpreted?\",\"answer\":\"The chart uses symbols where “++” indicates very good activity, “+” OK activity, “+/-” variable or poor, and “0” no activity. “R” denotes resistance developing, with a note to check locally for resistance patterns.\"},{\"question\":\"What does the chart emphasize about antibiotic activity across Gram-negative pathogens?\",\"answer\":\"It states that if an antibiotic works on Pseudomonas it has good activity against enteric GNRs, and if it works against enterics it often has activity against respiratory Gram negatives. It also notes relationships for alpha-hemolytic versus beta-hemolytic streptococci for similar reasons.\"},{\"question\":\"Which IV/PO agents are listed for serious MRSA and resistant Gram-positive cocci?\",\"answer\":\"The MRSA section lists vancomycin, linezolid, daptomycin, telavancin, ceftaroline, tige/erava IV and omadacycline PO, and lefamulin IV/PO. It also provides brief notes on typical strengths, sites of infection, and important cautions (e.g., long-term linezolid concerns with SSRIs, daptomycin inactivation by lung surfactant).\"}]","Antiantibiotic Chart - Gram-Positive Cocci and Gram-Negative Activity Guide | PDF"]